Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Duda

Showing results (251-260 of 338) with videos related to

Pageof 34
Sort By:
Cancer Research|October 15, 2009
Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancerLei Xu, Dan G Duda, Emmanuelle di Tomaso, et al.
Hepatology (Baltimore, Md.)|December 23, 2014
CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in miceYunching Chen, Rakesh R Ramjiawan, Thomas Reiberger, et al.
Plos One|June 16, 2012
Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancerJeffrey A Meyerhardt, Marek Ancukiewicz, Thomas A Abrams, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 22, 2015
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancerRebecca S Heist, Dan G Duda, Dushyant V Sahani, et al.
Nature Communications|December 8, 2025
Inhibiting B cells enhances the efficacy of STING agonism or immune checkpoint blockade in hepatocellular carcinomaXin Liu, Zelong Liu, Chengzhan Zhu, et al.
Cancers|November 27, 2021
Changes in Blood Biomarkers of Angiogenesis and Immune Modulation after Radiation Therapy and Their Association with Outcomes in Thoracic MalignanciesEleni Gkika, Sonja Adebahr, Anton Brenner, et al.
International Journal of Radiation Oncology, Biology, Physics|June 23, 2009
Radiation Therapy Oncology Group translational research program stem cell symposium: incorporating stem cell hypotheses into clinical trialsWendy A Woodward, Robert G Bristow, Michael F Clarke, et al.
Cancers|February 25, 2023
Inhibition of CXCR4 Enhances the Efficacy of Radiotherapy in Metastatic Prostate Cancer ModelsNisha Gupta, Hiroki Ochiai, Yoshinori Hoshino, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 10, 2012
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapyYuhui Huang, Jianping Yuan, Elda Righi, et al.
Cancer Research|January 5, 2011
Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escapeEmmanuelle di Tomaso, Matija Snuderl, Walid S Kamoun, et al.
Pageof 34

Showing results (251-260 of 338) with videos related to

Sort By:
Pageof 34
Cancer Research|October 15, 2009
Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancerLei Xu, Dan G Duda, Emmanuelle di Tomaso, et al.
Hepatology (Baltimore, Md.)|December 23, 2014
CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in miceYunching Chen, Rakesh R Ramjiawan, Thomas Reiberger, et al.
Plos One|June 16, 2012
Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancerJeffrey A Meyerhardt, Marek Ancukiewicz, Thomas A Abrams, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 22, 2015
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancerRebecca S Heist, Dan G Duda, Dushyant V Sahani, et al.
Nature Communications|December 8, 2025
Inhibiting B cells enhances the efficacy of STING agonism or immune checkpoint blockade in hepatocellular carcinomaXin Liu, Zelong Liu, Chengzhan Zhu, et al.
Cancers|November 27, 2021
Changes in Blood Biomarkers of Angiogenesis and Immune Modulation after Radiation Therapy and Their Association with Outcomes in Thoracic MalignanciesEleni Gkika, Sonja Adebahr, Anton Brenner, et al.
International Journal of Radiation Oncology, Biology, Physics|June 23, 2009
Radiation Therapy Oncology Group translational research program stem cell symposium: incorporating stem cell hypotheses into clinical trialsWendy A Woodward, Robert G Bristow, Michael F Clarke, et al.
Cancers|February 25, 2023
Inhibition of CXCR4 Enhances the Efficacy of Radiotherapy in Metastatic Prostate Cancer ModelsNisha Gupta, Hiroki Ochiai, Yoshinori Hoshino, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 10, 2012
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapyYuhui Huang, Jianping Yuan, Elda Righi, et al.
Cancer Research|January 5, 2011
Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escapeEmmanuelle di Tomaso, Matija Snuderl, Walid S Kamoun, et al.
Pageof 34